Blanco Sandra, Sanz-García Marta, Santos Claudio R, Lazo Pedro A
Programa de Oncología Traslacional, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Salamanca, Salamanca, Spain.
PLoS One. 2008 Feb 20;3(2):e1660. doi: 10.1371/journal.pone.0001660.
Cellular biological responses to specific stimulation are determined by a balance among signaling pathways. Protein interactions are likely to modulate these pathways. Vaccinia-related kinase-2 (VRK2) is a novel human kinase that can modulate different signaling pathways.
We report that in vivo, the activity of JIP1-JNK complexes is downregulated by VRK2 in response to interleukin-1beta. Also the reduction of endogenous VRK2 with shRNA increases the transcriptional response to IL-1beta. The JIP1 scaffold protein assembles three consecutive members of a given MAPK pathway forming signaling complexes and their signal can be modulated by interactions with regulatory proteins that remain to be identified. Knocking-down JIP1 with siRNA resulted in elimination of the AP1 transcriptional response to IL-1beta. VRK2, a member of novel Ser-Thr kinase family, is able to stably interact with JIP1, TAK1 and MKK7, but not JNK, and can be isolated forming oligomeric complexes with different proportions of TAK1, MKK7beta1 and JNK. JIP1 assembles all these proteins in an oligomeric signalosome. VRK2 binding to the JIP1 signalosome prevents the association of JNK and results in a reduction in its phosphorylation and downregulation of AP1-dependent transcription.
CONCLUSIONS/SIGNIFICANCE: This work suggests that the intracellular level of VRK2 protein can modulate the flow through a signaling pathway and alter the response from a receptor that can be distributed by more than one pathway, and thus contribute to the cellular specificity of the response by forming alternative signaling complexes. Furthermore, the effect might be more general and affect other signaling routes assembled on the JIP1 scaffold protein for which a model is proposed.
细胞对特定刺激的生物学反应由信号通路之间的平衡决定。蛋白质相互作用可能会调节这些通路。痘苗相关激酶2(VRK2)是一种新型人类激酶,可调节不同的信号通路。
我们报道,在体内,VRK2可响应白细胞介素-1β下调JIP1-JNK复合物的活性。此外,用短发夹RNA降低内源性VRK2可增强对IL-1β的转录反应。JIP1支架蛋白组装给定丝裂原活化蛋白激酶(MAPK)通路的三个连续成员形成信号复合物,其信号可通过与有待鉴定的调节蛋白相互作用来调节。用小干扰RNA敲低JIP1可消除对IL-1β的AP1转录反应。VRK2是新型丝氨酸-苏氨酸激酶家族的成员,能够与JIP1、转化生长因子β激活激酶1(TAK1)和丝裂原活化蛋白激酶激酶7(MKK7)稳定相互作用,但不与JNK相互作用,并且可以分离形成含有不同比例TAK1、MKK7β1和JNK的寡聚复合物。JIP1在寡聚信号小体中组装所有这些蛋白质。VRK2与JIP1信号小体的结合阻止了JNK的缔合,并导致其磷酸化减少以及AP1依赖性转录的下调。
结论/意义:这项工作表明,VRK2蛋白的细胞内水平可调节信号通路的流量,并改变来自可通过多种途径分布的受体的反应,从而通过形成替代信号复合物来促成反应的细胞特异性。此外,这种效应可能更具普遍性,并影响在JIP1支架蛋白上组装的其他信号途径,为此提出了一个模型。